Vikas Sinha, the Chief Financial Officer of $SRRK, sold 16,755 shares of the company on 01-13-2026 for an estimated $715,438. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.8% of their shares of this class of stock. Following this trade, they now own 583,245 shares of this class of $SRRK stock.
$SRRK Insider Trading Activity
$SRRK insiders have traded $SRRK stock on the open market 21 times in the past 6 months. Of those trades, 9 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $SRRK stock by insiders over the last 6 months:
- SRINIVAS AKKARAJU has made 9 purchases buying 530,038 shares for an estimated $19,988,985 and 0 sales.
- MO QATANANI (CHIEF SCIENTIFIC OFFICER) has made 0 purchases and 3 sales selling 142,993 shares for an estimated $6,379,160.
- DAVID HALLAL (Chief Executive Officer) sold 57,450 shares for an estimated $2,453,115
- AKSHAY VAISHNAW (President of R&D) sold 20,438 shares for an estimated $872,702
- VIKAS SINHA (Chief Financial Officer) sold 16,755 shares for an estimated $715,438
- KEITH WOODS (Chief Operating Officer) sold 16,746 shares for an estimated $715,054
- KATIE PENG has made 0 purchases and 4 sales selling 2,012 shares for an estimated $77,077.
- CARYN PARLAVECCHIO (CHRO) sold 2,178 shares for an estimated $67,880
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SRRK Hedge Fund Activity
We have seen 135 institutional investors add shares of $SRRK stock to their portfolio, and 96 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,521,022 shares (+124.5%) to their portfolio in Q3 2025, for an estimated $93,882,859
- HOLOCENE ADVISORS, LP added 2,461,596 shares (+inf%) to their portfolio in Q3 2025, for an estimated $91,669,835
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,878,592 shares (-21.4%) from their portfolio in Q3 2025, for an estimated $69,958,766
- COMMODORE CAPITAL LP removed 1,450,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $53,998,000
- JENNISON ASSOCIATES LLC added 1,240,566 shares (+339.0%) to their portfolio in Q3 2025, for an estimated $46,198,677
- POINT72 ASSET MANAGEMENT, L.P. added 874,377 shares (+660.7%) to their portfolio in Q3 2025, for an estimated $32,561,799
- DRIEHAUS CAPITAL MANAGEMENT LLC added 846,444 shares (+71.9%) to their portfolio in Q3 2025, for an estimated $31,521,574
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SRRK Analyst Ratings
Wall Street analysts have issued reports on $SRRK in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Wolfe Research issued a "Outperform" rating on 11/18/2025
- JP Morgan issued a "Overweight" rating on 11/18/2025
- Barclays issued a "Overweight" rating on 11/17/2025
- B of A Securities issued a "Buy" rating on 10/09/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/23/2025
- Jefferies issued a "Buy" rating on 08/21/2025
To track analyst ratings and price targets for $SRRK, check out Quiver Quantitative's $SRRK forecast page.
$SRRK Price Targets
Multiple analysts have issued price targets for $SRRK recently. We have seen 11 analysts offer price targets for $SRRK in the last 6 months, with a median target of $50.0.
Here are some recent targets:
- Geoff Meacham from Citigroup set a target price of $55.0 on 01/09/2026
- Michael Yee from UBS set a target price of $60.0 on 01/07/2026
- Etzer Darout from Barclays set a target price of $52.0 on 12/17/2025
- Tessa Romero from JP Morgan set a target price of $47.0 on 11/18/2025
- Kalpit Patel from Wolfe Research set a target price of $42.0 on 11/18/2025
- Srikripa Devarakonda from Truist Securities set a target price of $44.0 on 10/20/2025
- Tazeen Ahmad from B of A Securities set a target price of $53.0 on 10/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
